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BACKGROUND: Poorly differentiated thyroid carcinomas (PDTC) represent a heterogeneous, aggressive entity, presenting features that
suggest a progression from well-differentiated carcinomas. To elucidate the mechanisms underlying such progression and identify
novel therapeutic targets, we assessed the genome-wide expression in normal and tumour thyroid tissues.
METHODS: Microarray analyses of 24 thyroid carcinomas – 7 classic papillary, 8 follicular variants of papillary (fvPTC), 4 follicular (FTC)
and 5 PDTC – were performed and correlated with RAS, BRAF, RET/PTC and PAX8-PPARG alterations. Selected genes were validated
by quantitative RT–PCR in an independent set of 28 thyroid tumours.
RESULTS: Unsupervised analyses showed that gene expression similarity was higher between PDTC and fvPTC, particularly for
tumours harbouring RAS mutations. Poorly differentiated thyroid carcinomas presented molecular signatures related to cell
proliferation, poor prognosis, spindle assembly checkpoint and cell adhesion. Compared with normal tissues, PTC had 307 out of 494
(60%) genes over-expressed, FTC had 137 out of 171 (80%) genes under-expressed, whereas PDTC had 92 out of 107 (86%) genes
under-expressed, suggesting that gene downregulation is involved in tumour dedifferentiation. Significant UHRF1 and ITIH5
deregulated gene expression in PDTC, relatively to normal tissues, was confirmed by quantitative RT–PCR.
CONCLUSION: Our findings suggest that fvPTC are possible precursors of PDTC. Furthermore, UHRF1 and ITIH5 have a potential
therapeutic/prognostic value for aggressive thyroid tumours.
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Most thyroid neoplasias derive from follicular cells and show a
wide range of biological behaviours from indolent to highly
invasive cancers (DeLellis et al, 2004). Well-differentiated thyroid
cancers (WDTC), such as papillary thyroid carcinoma (PTC) and
follicular thyroid carcinoma (FTC), are usually treated successfully
with surgery and radioactive iodine; however, poorly differentiated
thyroid carcinoma (PDTC) and anaplastic (or undifferentiated)
thyroid carcinoma (ATC) can behave aggressively with no effective
form of treatment (Patel and Shaha, 2006).
Previous reports suggest a model of progression from WDTC
to PDTC and to ATC. PDTC show limited follicular cell
differentiation and are, both morphologically and behaviourally,
positioned between well- and undifferentiated carcinomas (DeLel-
lis et al, 2004). Indeed, cases of WDTC containing areas of poor-
or undifferentiation, as well as, cases of PDTC/ATC containing
well-differentiated areas, have been widely detected (Lam et al,
2000). Progression is further suggested by the sequential increase
in chromosomal abnormalities from WDTC to PDTC and
ATC (Wreesmann et al, 2002; Rodrigues et al, 2004). Mutations
in the RAS and BRAF genes also support a model of tumour
progression, as the frequency of these events in PDTC is midway
between well-differentiated and undifferentiated carcinomas,
rather than being randomly distributed (Garcia-Rostan et al,
2003; Nikiforova et al, 2003). Other alterations, such as tumour
suppressor TP53 mutations, are specifically found in PDTC
and ATC, and are often associated with RAS or BRAF muta-
tions (Quiros et al, 2005; Wang et al, 2007), suggesting an
accumulation of events during progression. Nevertheless, it is
not clear whether PDTC derive from either PTC or FTC, or
whether they arise de novo. In addition, the genetic and epi-
genetic mechanisms underlying the process remain ill
defined.
Genome-wide expression analysis has been successfully used
to identify molecular signatures, improving the diagnosis and
prognosis of several types of tumours (Quackenbush, 2006).
For thyroid neoplasias, one of the earliest reports of genome-
wide expression analysis described a consistent gene
expression profile that distinguished PTC from normal cells
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s(Huang et al, 2001). Most of the genes identified in this work were
corroborated in subsequent studies. Gene expression studies have
also been used to differentiate benign from malignant thyroid
tumours, and correlate gene expression patterns with specific
mutations or rearrangements in PTC and FTC (for review,
see Eszlinger et al, 2007).
To our knowledge, only two studies have addressed the genome-
wide expression of PDTC. One of these studies compared
gene expression of PDTC and ATC cell lines to normal thyroid
tissue, and showed that these cells presented largely altered
expression profiles that have been associated with the cancer
process (Rodrigues et al, 2007). Although the authors confirmed
some of the abnormal expressed genes in primary tumours, it has
been shown that immortal cell lines may not fully reflect the
functional aspects of the tumours, and that some molecular
processes might be specifically acquired during the immortalisa-
tion step (Dairkee et al, 2004). In the other study, which used
WDTC, PDTC and ATC primary tumours, deregulation of different
molecular pathways, such as the MAPK signalling pathway, focal
adhesion and cell motility, cell proliferation and cell-cycle
progression, was associated with dedifferentiation in PDTC and
ATC (Montero-Conde et al, 2008).
In this study, we used the array platform GeneChip Human
Genome U133 Plus 2.0 (HG-U133 Plus 2.0) to analyse the
expression of a wide range of genes (430000) in well- and poorly
differentiated thyroid tumours and, to correlate, for the first time,
gene expression with BRAF, RAS, RET/PTC and PAX8-PPARG
alterations.
MATERIALS AND METHODS
Tissue samples
Both tumour and normal thyroid tissue samples were obtained at
time of surgery, and were immediately frozen in liquid nitrogen.
Histological classifications followed the criteria described in World
Health Organization (WHO) classification of thyroid tumours
(DeLellis et al, 2004). All samples were obtained with permission,
and the project was approved by our institution ethical committee.
The microarray sample set consisted of a total of 24 tumour
samples – 5 PDTC, 7 classic PTC (cPTC), 8 follicular variants of
PTC (fvPTC) and 4 FTC (Supplementary Table 1). A pool of
human thyroid total RNA obtained from 65 Caucasian individuals
with 18–61-years old, whom died from sudden death (BD
Bioscience, Franklin Lakes, NJ, USA), and 2 normal tissue samples
taken from the opposite lobe of thyroid tumours, were also
processed.
An independent sample set, consisting of five PDTC, seven
cPTC, seven fvPTC, nine FTC and six normal thyroid tissues taken
from the opposite lobe of thyroid tumours, was used for
quantitative real-time RT–PCR. Expression was also studied in
two poorly differentiated thyroid cancer cell lines, T243 and T351
(described earlier by Rodrigues et al, 2007), kindly supplied by
Dr Lu ´cia Roque, from Centro de Investigac¸a ˜o de Patobiologia
Molecular (CIPM), Instituto Portugue ˆs de Oncologia de Lisboa
Francisco Gentil, Lisbon, Portugal.
Total RNA isolation/extraction
Total RNA was extracted and purified using the RNeasy Mini
kit (Quiagen, Hamburg, GmbH, Germany) according to the
manufacturer’s protocol, and quantified by UV spectrophotometry
(NanoDrop ND-1000, Thermo Fisher Scientific, Wilmington,
DE, USA). RNA integrity was assessed by micro capillary
electrophoresis (Agilent 2100 Bioanalyzer, Santa Clara, CA, USA)
and samples with RNA Integrity Number equal or higher than 7.7
were selected for microarray analysis.
RNA processing and hybridisation
RNA samples were processed following the one-cycle eukaryo-
tic target labelling protocol from Affymetrix, and were hybridi-
sed using the HG-U133 Plus 2.0 Array (Affymetrix, Santa
Clara, CA, USA). Hybridisation results were scanned using the
GeneChip Scanner 3000 and stored in the GeneChip Operating
Software.
Microarray data analysis
Partek Genomics Suite Software (Partek Inc, St Louis, MO, USA)
was used for unsupervised analyses. First, array data were
normalised and the expression levels were determined applying
the robust multi-array average method (Irizarry et al, 2003), and
data were corrected for non-biological factors. Samples were
represented three dimensionally, according to the expression levels
of all probe sets, by principal components analysis (PCA). Probe-
sets data were also used to obtain a dendogram of the samples, by
hierarchical clustering, with the Pearson correlation coefficient.
DNA-ChipAnalyzer (dChip) 2006 software (Li and Wong, 2001)
was used to obtain differentially expressed genes between groups.
Arrays were normalised with the invariant set normalisation
method and expression levels were calculated by model-based
expression analysis with perfect match-only model. Probe sets that
were absent in all samples or those that did not change across
samples (coefficient of variation lower than 0.2 and higher than 10)
were eliminated from further analysis. Probe sets were considered
to be differentially expressed between two groups when the lower
90% limit of the confidence interval of the fold change (ratio of the
expression level in the two groups) was equal or higher than two-
fold, with an unpaired t-test considered significant at Pp0.01.
Onto-Express from Onto-Tools package (Khatri et al, 2002) was
used to classify genes differentially expressed according to their
biological role.
Gene set enrichment analysis (GSEA) software (Subramanian
et al, 2005) was used to determine whether members of defined
groups of genes, which share common features (gene sets), are
preferentially placed towards the top or the bottom of a list of
genes. In this list, genes were ranked according to the differential
expression between two sample groups. This method was applied
using two catalogues of gene sets: one whose products are involved
in specific pathways/functions and another defined by expression
neighbourhoods, which indicates molecular signatures associated
with cancer-related genes. Statistical significance was estimated by
a nominal P value obtained by phenotype permutation. P values
were corrected for multiple hypothesis testing using false discovery
rate and family wise-error rate (FWER). Gene sets were considered
significant at Po0.05 and with FWERp0.25.
First-strand cDNA synthesis
cDNA was synthesised from 1mg of total RNA (for cDNA sequence
analysis) or 2mg of total RNA (for quantitative RT–PCR), at 371C
for 90min, using random primer p(dN)6 (Roche Diagnostics
Corporation, Indianapolis, IN, USA) and SuperScript II reverse
transcriptase (Invitrogen, Paisley, UK).
Mutational analysis of the RAS, BRAF genes and
PAX8-PPARG, RET/PTC rearrangements
Mutational analysis was undertaken using cDNA from the tumour
samples of the microarray set. PTC were screened for BRAF
mutations and rearrangements of RET/PTC and, in addition,
follicular variants were also analysed for RAS mutations and
PAX8-PPARG rearrangements. FTC were screened for RAS and
PAX8-PPARG rearrangements. PDTC were analysed for BRAF, RAS
and PAX8-PPARG genes. Primers were designed to amplify exon
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s15 of the BRAF gene, exons 2 and 3 of the N-, KRAS genes and
exons 1 and 2 of the HRAS gene. Primers flanking the respective
fusion points were used to screen the presence of RET/PTC1,
RET/PTC2, RET/PTC3 and PAX8-PPARG fusion transcripts,
as described earlier (Marques et al, 2002; Rebelo et al, 2003).
Sequencing analysis, to search for mutations and to confirm the
rearrangements, was performed with the same primers as for PCR,
using the Big Dye Terminator v1.1 Cycle Sequencing kit (Applied
Biosystems, Foster City, CA, USA), according to the manufac-
turer’s protocol. Sequencing products were separated in an ABI
Prism 310 Genetic Analyser (Applied Biosystems) and analysed
with the Sequence Analysis Software version 3.4.1 (Applied
Biosystems). Primer sequences and assay conditions are available
on request.
Quantitative real-time RT–PCR
Real-time RT–PCR assays were performed in 96-well reaction
plates (MicroAmp Optical 96-Well Reaction Plate; Applied
Biosystems) on an ABI Prism 7900 HT Sequence Detection System
(Applied Biosystems) with the SDS Software version 2.3 (Applied
Biosystems). PCR amplifications were performed using for
each gene, pre-developed primers and probe (Inventoried
TaqMan Gene Expression Assays ID: Hs00218544_m1 (PBK);
Hs00273589_m1 (UHRF1); Hs00228960_m1 (ITIH5); Applied
Biosystems), and TaqMan Universal PCR Master Mix (Applied
Biosystems), according to the manufacturer’s protocol. To
normalise differences in the amount of template used, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) transcript was used as
an endogenous control (Pre-Developed TaqMan Assay Reagents
Human GAPDH; Applied Biosystems). Two-fold serial dilutions
were used to apply the relative standard curve method. A pool of
five normal thyroid tissues was used as calibrator to determine the
relative expression in samples. All reactions, including a control
without template, were performed in triplicate.
Quantitative RT–PCR results were analysed using the GraphPad
Prism version 4.00 (GraphPad Software, Inc). Intensity levels
were calculated as mean±standard error of the mean (s.e.m.).
Comparisons between sample groups were performed using the
Kruskal–Wallis with Dunn’s Multiple Comparison test, because
samples distribution was not Gaussian or variances between
groups were not equal. Correlations of quantitative RT–PCR data
with other variables were performed using the Pearson or the
Spearman correlations (for a non-Gaussian distribution). The
correlations and differences between group means were considered
significant at Po0.05.
RESULTS
Mutation screening
Tumour samples were screened for mutations in MAPK pathway
effectors, which are frequently mutated in thyroid cancer
(Supplementary Table 1). The BRAF V600E substitution was only
present in cPTC, accounting for 57.1% (four out of seven) of the
cases. On the other hand, mutations of N-o rKRAS genes were
observed in 50% (four out of eight) of the fvPTC and in 40% (two
out of five) of PDTC. All FTC (n¼4) were RAS negative. The
PAX8-PPARG fusion gene was found in 12.5% (one out of eight) of
fvPTC and in 25% (one out of four) of FTC. No RET/PTC1,- 2 or -3
rearrangements were identified in PTC. However, as other
rearrangements involving the RET (Ciampi et al, 2007) or NTRK1
(Pierotti and Greco, 2006) genes have also been described in PTC,
we specifically analysed RET and NTRK1 microarray mRNA
expression in PTC negative for mutations. In one cPTC (sample
2 – Supplementary Table 1), a 20-fold increase in RET expression
was detected in comparison to the other samples. FISH confirmed
the presence of a RET/PTC rearrangement in 37% (71 out of 194)
of these tumour cells (data not shown).
Unsupervised analyses for global gene expression profiling
We carried out unsupervised analyses to examine the relationship
between gene expression, tumour histotype and mutational status.
Global gene expression similarity between the 27 samples was
examined using hierarchical clustering (Figure 1). As represented
on the dendrogram, distinct profiles separated FTC from the other
tumours. Interestingly, a case of fvPTC diffuse (or multinodular)
with a PAX8-PPARG rearrangement clustered with FTC. Different
molecular signatures were present in the PTC sub-set: cPTC
formed a separate sub-group from fvPTC and, among these PTC
subtypes, samples with RAS/BRAF mutations were separated from
samples without mutations. By PCA of data for all probe sets,
which represents the samples three dimensionally according to the
global gene expression profile, the FTC and the fvPTC diffuse (or
multinodular) also formed a group apart from the other tumours
and normal thyroid samples, which tended to cluster together
(Supplementary Figure 1; Supplementary Movie 1). PDTC samples,
particularly those with RAS mutations, clustered with PTC in both
representations.
Genes differentially expressed between tumours and
normal tissue
Differentially expressed genes were defined as those with an
expression level equal, or higher, than two-fold in a group
relatively to another, with a P valuep0.01. We compared each
cPTC
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Figure 1 Global gene expression similarity between samples using the
unsupervised hierarchical clustering method. In the dendogram, distance
separating samples represents the gene expression resemblance between
them. The result of mutational analysis for each tumour specimen is shown.
Wild-type (wt) label denotes absence of mutation in screened genes;
aQ61R mutant of NRAS;
bG13R mutant of KRAS;
cV600E mutant of BRAF;i n
parenthesis is indicated the sample number assigned in Supplementary
Table 1. cPTC¼classic papillary thyroid carcinoma; FTC¼follicular thyroid
carcinoma; fvPTC¼follicular variant of papillary thyroid carcinoma;
PDTC¼poorly differentiated thyroid carcinoma; n.a.¼not applicable.
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stumour group (cPTC, fvPTC, FTC and PDTC) with the three
normal thyroid samples, and we found over-expression of about
60% of probe sets for both cPTC and fvPTC, whereas in FTC and
PDTC, about 80% of the probe sets were under-expressed
(Figure 2). PDTC had 92 downregulated genes relatively to normal
tissues (Supplementary Table 2), but only 15 out of the 107 genes
differentially expressed were over-expressed (Table 1).
The biological processes mainly represented by the probe sets
differentially expressed between thyroid tumours and normal
tissues were the signal transduction, cell adhesion, regulation of
transcription and cell proliferation/cell cycle (Supplementary
Figure 2). We were also able to identify 11 probe sets that were
under-expressed in all tumours comparatively to normal tissues
(Table 2).
Genes specific for PDTC
The PDTC group had 3, 8 and 1 over-expressed probe sets and 11,
154 and 59 under-expressed probe sets compared with FTC, cPTC
and fvPTC, respectively (data not shown). Only two probe sets
were consistently under-expressed in the PDTC tumour set
comparatively to the WDTC (Table 1).
GSEA for PDTC
GSEA is another method for interpreting gene expression data that
focus on groups of genes sharing common biological function,
chromosomal location or regulation. This approach can show
important effects on pathways, which might be missed in single-
gene analysis (Subramanian et al, 2005). We applied this
methodology to identify pathways altered in thyroid tumour
progression. There were no statistically significant functional-
defined gene sets enriched in PDTC samples vs WDTC, still we
analysed the 20 most relevant results (Table 3). The budding
uninhibited by benzimidazoles 1 homolog (yeast) (BUB1) was the
most represented gene being present in 13 of the 20 gene sets.
Cell division cycle 2, G1–S and G2–M (CDC2) and Cyclin B2
(CCNB2) were represented in 12 of the 20 gene sets, and 10 gene
sets contained MAD2 mitotic arrest-deficient-like 1 (yeast)
(MAD2L1), topoisomerase (DNA) II a 170kDa (TOP2A),
cyclin-dependent kinase inhibitor 3 (CDK2-associated dual
specificity phosphatase) (CDKN3) and centromere protein A
(CENPA). In addition, statistically significant molecular signatures
of four deregulated genes, which are involved in the cancer
process, were identified in PDTC (Table 3 – Expression
neighbourhoods-defined gene sets).
Validation of microarray gene expression
Real-Time RT–PCR was performed to validate three genes
differentially expressed between PDTC and normal thyroid
samples: ubiquitin-like, containing PHD and RING finger
domains, 1 (UHRF1), PDZ-binding kinase (PBK) and inter-alpha
(globulin) inhibitor H5 (ITIH5). This validation was processed in
an independent sample set of 28 tumours (Figure 3). UHRF1 and
PBK had increased expression in all tumour samples relatively to
normal tissue samples, but the highest expression levels were
detected in PDTC. Differences in the UHRF1 expression
(Figure 3B) between PDTC and normal tissue were statistically
significant (11.77±3.07 vs 1.77±0.36; Po0.01), even if only
considering the expression in the independent set (14.30±5.49 vs
1.77±0.36; Po0.05) (Figure 3A). On the other hand, differences in
the PBK expression were not statistically significant (Figures 3C
and D). ITIH5 expression was decreased in all tumours samples
relatively to normal tissues (Figures 3E and F). Statistically
significant differences were detected in all tumour groups
relatively to normal samples, except in cPTC (PDTC: 0.22±0.17,
Po0.001; FTC: 0.15±0.05, Po0.001; fvPTC: 0.22±0.03, Po0.05 vs
normal: 1.00±0.10). Differences were also significant when
considering the independent set of samples (PDTC: 0.41±0.33,
cPTC
Normal
325 genes
118
genes
207
genes
Normal
fvPTC
169 genes
69
genes
100
genes
PDTC
Normal
107 genes
92
genes
15
genes
Normal
FTC
171 genes
137
genes
34
genes
0 1.0 2.0 3.0 -1.0 -2.0 -3.0
Figure 2 Expression profile of the genes differentially expressed between tumours and normal tissues. Each tumour histology was compared with the
normal thyroid tissues and expression levels of the genes differentially expressed were represented. Expression levels are indicated by colour intensities in
which green and red correspond, respectively, to a lower and a higher expression than the mean value for the gene, in all samples being compared. On the
left of each profile, the number of under- and over-expressed genes in the tumour set is shown. At the bottom, the total number of differentially expressed
genes is indicated. Only one probe set was considered for each gene. cPTC¼classic papillary thyroid carcinoma; FTC¼follicular thyroid carcinoma;
fvPTC¼follicular variant of papillary thyroid carcinoma; PDTC¼poorly differentiated thyroid carcinoma.
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sPo0.05; FTC: 0.14±0.07, Po0.001 vs normal: 1.00±0.10).
Additionally, we assessed UHRF1 and ITIH5 expressions in two
PDTC cell lines. No significant increase in UHRF1 expression was
detected (mean±standard deviation: 1.86±0.16 and 1.43±0.16 vs
1.77±0.36). On the other hand, ITIH5 expression was undetectable
(Ct values437) in both cell lines. Correlation of quantitative
RT–PCR data with the expression levels obtained in the
microarray analysis was statistically significant (Pearson correla-
tion r¼0.61 for UHRF1 with P¼0.0015; Spearman correlation
r¼0.70 for PBK with P¼0.0001; Pearson correlation r¼0.94 for
ITIH5 with Po0.0001). There was no correlation of gene
expression with tumour size, gender or age, except for ITIH5,
whose decreased expression was associated with larger tumours
(Spearman correlation r¼  0.33 with P¼0.02).
Table 1 Main characteristics of differentially expressed genes in poorly differentiated tumours
Probe set Gene name in array HG-U133 Plus 2.0
Official
symbol
a
Accession
number
Biological
process
b LBFC P-value
Genes over-expressed in PDTC vs normal thyroid tissues
204170_s_at CDC28 protein kinase regulatory subunit 2 CKS2 NM_001827 Cell cycle 5.43 4.68E–03
219148_at PDZ binding kinase PBK NM_018492 Cell cycle 4.29 8.04E 03
202503_s_at KIAA0101 KIAA0101 NM_014736 Cell cycle 3.46 5.80E 03
205034_at Cyclin E2 CCNE2 NM_004702 Cell cycle 2.95 6.21E 03
202975_s_at Rho-related BTB domain containing 3 RHOBTB3 N21138 — 2.94 9.42E 03
218096_at 1-acylglycerol-3-phosphate O-acyltransferase
5 (lysophosphatidic acid acyltransferase, epsilon)
AGPAT5 NM_018361 Phospholipid
metabolism
2.76 4.23E 03
225655_at Ubiquitin-like, containing PHD and RING finger domains, 1 UHRF1 AK025578 Cell cycle 2.61 8.96E 03
229551_x_at Zinc-finger protein 367 ZNF367 N62196 Transcription
regulation
2.59 6.36E 04
220608_s_at Homo sapiens PRO1914 protein (PRO1914) ZNF770 NM_014106 Transcription
regulation
2.58 2.73E 03
222848_at Leucine zipper protein FKSG14 CENPK BC005400 Transcription
regulation
2.53 4.85E 04
224726_at Mindbomb homolog 1 (Drosophila) MIB1 W80418 Notch signaling 2.38 1.98E 04
220145_at ASAP MAP9 NM_024826 Cell cycle 2.07 6.36E 03
218819_at DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26 INTS6 NM_012141 snRNA
processing
2.05 3.30E 03
235609_at BRCA1 interacting protein C-terminal helicase 1 BRIP1 BF056791 DNA DBS
repair
2.05 7.46E 03
203007_x_at Lysophospholipase I LYPLA1 AF077198 Phospholipid
metabolism
2.03 2.24E 03
Genes under-expressed in PDTC vs WDTC
225119_at Chromatin modifying protein 4B CHMP4B AW299290 Protein
transport
 2.97 0.00
204524_at 3-phosphoinositide-dependent protein kinase-1 PDPK1 NM_002613 Cell adhesion  2.61 0.00
Abbreviations: DBS¼double-strand breaks; LBFC¼lower bound of fold change; snRNA¼small nuclear RNA.
aAssigned in EntrezGene.
bInformation taken from Online
Mendelian Inheritance in Man (OMIM) or from EntrezGene. P values for difference in mean expression between groups were calculated using an unpaired t-test.
Table 2 Main characteristics of differentially expressed genes in the four thyroid tumour histotypes vs normal thyroid tissues
Probe set
Gene name in array HG-U133
Plus 2.0
Official
symbol
a
Accession
number Biological process
b LBFC P-value
Under-expressed genes in the four types of tumours vs normal thyroid tissues
205382_s_at D component of complement (adipsin) CFD NM_001928 Immune response  9.31 4.74E 03
204606_at Chemokine (C-C motif) ligand 21 CCL21 NM_002989 Inflammatory response  7.57 5.72E 03
235849_at Hypothetical protein MGC45780 SCARA5 BE787752 Immune response  6.38 9.25E 03
205350_at Cellular retinoic acid binding protein 1 CRABP1 NM_004378 Retinoic acid metabolism  6.13 5.13E 03
203060_s_at 30-phosphoadenosine 50-
phosphosulfate synthase 2
PAPSS2 AF074331 Sulfur metabolism  5.98 8.55E 04
212713_at Microfibrillar-associated protein 4 MFAP4 R72286 Cell adhesion  4.20 3.81E 04
1556427_s_at Similar to hypothetical protein LOC221091 AL834319 —  4.07 5.57E 03
219778_at Zinc-finger protein, multitype 2 ZFPM2 NM_012082 Transcription regulation  4.03 7.60E 03
205413_at Chromosome 11 open reading frame 8 MPPED2 NM_001584 Nervous system development  3.59 9.00E 05
206201_s_at Mesenchyme homeo box 2 (growth
arrest-specific homeo box)
MEOX2 NM_005924 Development  2.92 5.85E 03
217525_at Olfactomedin-like 1 OLFML1 AW305097 Cell proliferation  2.64 2.34E 04
Abbreviation: LBFC¼lower bound of fold change.
aAssigned in EntrezGene.
bInformation taken from Online Mendelian Inheritance in Man (OMIM) or from EntrezGene. P values
for difference in mean expression between tumours and normal tissues were calculated using an unpaired t-test.
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sTable 3 Gene sets enriched in the poorly differentiated vs the well-differentiated groups
Gene set name
a Gene set description
Nominal
P-value FDR FWER Reference
Functional-defined gene sets
LEE_TCELLS3_UP Enriched in both intrathymic T
progenitor cells and CD3
intCD4
+CD8
+ thymocytes
1.01E 02 0.95 0.43 Lee et al (2004)
YU_CMYC_UP C-Myc activated genes 6.93E 03 0.56 0.47 Yu et al (2005)
GREENBAUM_E2A_UP Upregulated in E2A-deficient pre-B-cell lines 5.14E 03 0.44 0.51 Greenbaum et al (2004)
VANTVEER_BREAST_OUTCOME_
GOOD_VS_POOR_DN
Poor prognosis marker genes in breast cancer 7.61E 03 0.38 0.55 van’t Veer et al (2002)
MANALO_HYPOXIA_DN Genes downregulated in human pulmonary
endothelial cells under hypoxic conditions
8.89E 03 0.31 0.55 Manalo et al (2005)
ADIP_DIFF_CLUSTER5 Strongly upregulated at 24h during differentiation
of 3T3-L1 fibroblasts into adipocytes
2.40E 02 0.32 0.62 Burton et al (2002)
CANCER_UNDIFFERENTIATED_
META_UP
Genes commonly upregulated in undifferentiated
cancer relative to well-differentiated cancer
1.64E 02 0.30 0.64 Rhodes et al (2004)
HUMAN_TISSUE_TESTIS Genes expressed specifically in human testis tissue 1.15E 02 0.34 0.70 Su et al (2002)
ZHAN_MM_CD138_PR_VS_REST Top ranked over-expressed genes in proliferation
subgroup of bone marrow plasma cells from multiple
myeloma patients
9.83E 03 0.31 0.70 Zhan et al (2006)
CROONQUIST_IL6_STARVE_UP Genes upregulated in multiple myeloma cells exposed
to cytokine IL6 vs IL6-starved cells
7.21E 03 0.29 0.71 Croonquist et al (2003)
BRCA_PROGNOSIS_NEG Negatively correlated with metastasis and poor
prognosis in breast cancer
1.37E 02 0.28 0.73 Van’t Veer et al (2002)
P21_ANY_DN Downregulated after ectopic expression of
p21 (CDKN1A) in ovarian cancer cell line
2.12E 02 0.27 0.74 Wu et al (2002)
DOX_RESIST_GASTRIC_UP Upregulated in gastric cancer cell lines resistant
to doxorubicin, compared with parent
chemosensitive lines
1.94E 02 0.31 0.80 Kang et al (2004)
CROONQUIST_IL6_RAS_DN Genes downregulated in multiple myeloma cells
exposed to IL6 vs NRAS activating mutations cells
1.73E 02 0.29 0.80 Croonquist et al (2003)
REN_E2F1_TARGETS E2F1 targets in primary fibroblast WI-38 2.84E 02 0.28 0.81 Ren et al (2002)
BREAST_DUCTAL_CARCINOMA_
GENES
Genes upregulated in high tumour grade breast
tumours progressing from pre-invasive ductal
carcinoma in situ to invasive ductal carcinoma
2.43E 02 0.30 0.84
a
SERUM_FIBROBLAST_CELLCYCLE Cell-cycle-dependent genes, regulated after
exposure to serum in a variety of human
fibroblast cell lines
5.04E 02 0.28 0.85 Chang et al (2004)
BRENTANI_CELL_CYCLE Cancer-related genes involved in the cell cycle 1.87E 02 0.28 0.86 Brentani et al (2003)
SHEPARD_CRASH_AND_BURN_
MUT_VS_WT_DN
Genes upregulated in wild-type zebrafish
compared with the B-Myb loss-of-fuction mutants
2.13E 02 0.28 0.86 Shepard et al (2005)
GOLDRATH_CELLCYCLE Cell-cycle genes induced during antigen
activation of CD8
+ T cells
2.50E 02 0.27 0.87 Goldrath et al (2004)
Expression neighbourhoods-defined gene sets
GNF2_CKS1B Expression neighbourhood of CKS1B
in the GNF2 expression compendium
0.00 0.04 0.02
a
MORF_BUB1 Expression neighbourhood of BUB1 in
the MORF expression compendium
4.74E-03 0.14 0.10
a
MORF_BUB1B Expression neighbourhood of BUB1B in
the MORF expression compendium
0.00 0.20 0.19
a
GNF2_ESPL1 Expression neighbourhood of ESPL1
in the GNF2 expression compendium
9.59E-03 0.18 0.21
a
Abbreviations: BUB1¼budding uninhibited by benzimidazoles 1 homolog (yeast); BUB1B¼budding uninhibited by benzimidazoles 1 homolog beta (yeast); CD¼cluster of
differentiation; IL6¼interleukin 6; CDKN1A¼cyclin-dependent kinase inhibitor 1A (p21, Cip1); CKS1B¼CDC28 protein kinase regulatory subunit 1B; ESPL1¼extra spindle
pole bodies homolog 1 (S. cerevisiae); FDR¼false discovery rate; FWER¼family wise-error rate.
aAssigned in Molecular Signatures Database (www.broad.mit.edu/gsea/msigdb/
index.jsp). References are supplied as supplementary data.
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sDISCUSSION
The more aggressive thyroid carcinomas (PDTC and ATC) have
high malignant potential and it is not yet clear whether they arise
from pre-existing indolent WDTC or whether they arise de novo.
Some PDTC cases bear areas of pre-existing PTC and have a signifi-
cant prevalence of BRAF mutations (Nikiforova et al, 2003).
Others, instead of BRAF,f r e q u e n t l yd i s p l a yRAS mutations (Garcia-
Rostan et al, 2003), which are typically detected in follicular thyroid
adenomas, FTC and fvPTC. Comparative Genomic Hybridisation
(CGH) studies showed that among 11 copy number changes present
in PTC, 8 were also present in the PDTC set, thus suggesting
common genetic pathways (Wreesmann et al, 2002).
In our work, we were able to identify distinct gene expression
profiles among different thyroid tumour histotypes. Our results
suggest that PDTC have a gene expression profile closer to PTC, in
particular to the follicular variant, than to FTC. In fact, for PDTC
harbouring RAS mutations, a clear similarity to the gene profile of
RAS-mutated fvPTC was observed. Interestingly, these RAS-
mutated PDTC, presented papillary like nuclei. In keeping with
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Figure 3 Expression of the UHRF1, PBK and ITIH5 genes in different tumour histotypes, assessed by quantitative RT–PCR. Relative mRNA levels for
UHRF1 (A, B), PBK (C, D) and ITIH5 (E, F) were assessed in an independent sample set (left panel) and in the entire sample set, comprising the microarray
and the independent sample sets (right panel). Expression levels were normalised with the GAPDH expression and determined relatively to a calibrator.
Error bars denote±s.e.m. The P values for difference in mean expression between groups were performed using the Kruskal–Wallis with Dunn’s Multiple
Comparison test. These genes could not be assayed in one cPTC from the microarray set, PBK could not be evaluated in one PDTC sample, as well as, ITIH5
in one fvPTC and one cPTC from microarray set. cPTC¼classic papillary thyroid carcinoma; FTC¼follicular thyroid carcinoma; fvPTC¼follicular variant of
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sour findings, it has been observed that fvPTC, in contrast to cPTC,
are more frequently aneuploid (Wreesmann et al, 2004), a feature
common in PDTC. Therefore, fvPTC are likely to be precursors of
PDTC, particularly those cases harbouring RAS mutations.
We also analysed the differential gene expression between
tumours and normal thyroid tissues. PTC cases had slightly more
over- than under-expressed probe sets, confirming previous
reports (Huang et al, 2001). On the other hand, FTC and PDTC
had clearly a predominance of downregulated probe sets, which is
also in accordance with others (Aldred et al, 2003; Rodrigues et al,
2007). Studies have shown that allelic losses are clearly more
frequent in FTC and PDTC than in PTC (Ward et al, 1998;
Rodrigues et al, 2004). This could account for the differences in
gene expression as a genomic loss could, theoretically, originate
under-expression of genes. Epigenetic mechanisms, such as DNA
hypermethylation, are also likely to explain these expression
profiles. Indeed, increased frequency of hypermethylated CpG
islands is a common alteration in tumour progression.
Eleven probe sets were simultaneously under-expressed in all
tumours relatively to normal tissues, suggesting that these genes
may have important suppressor activity in thyroid tumourigenesis.
Among these, metallophosphoesterase domain containing 2
(MPPED2) and cellular retinoic acid-binding protein 1 (CRABP1)
under-expression have already been observed in thyroid tumours
(Griffith et al, 2006).
As observed earlier in other genome-wide studies, comparing
clinically aggressive PTC with differentiated PTC cases (Fluge et al,
2006) or comparing PDTC with normal tissue (Rodrigues et al,
2007) or with WDTC (Montero-Conde et al, 2008), we found that
many of the genes differentially upregulated in PDTC relatively to
normal tissues were associated with the cell-cycle, indicating that
the deregulation of this process is crucial in the progression to
more aggressive thyroid tumours. In particular, we identified genes
with major roles in mitosis, such as CDC28 protein kinase
regulatory subunit 2 (CKS2) and cyclin E2 (CCNE2), which have
been reported as over-expressed in various types of tumours
(Gudas et al, 1999; Scrideli et al, 2008).
We selected three genes for real-time RT–PCR analysis, which
were shown in the microarray analysis, to be differentially over-
expressed (PBK and UHRF1) and under-expressed (ITIH5)
between PDTC and normal thyroid tissues. UHRF1 and ITIH5
expressions were statistically different between PDTC and normal
thyroid samples. Although not statistically significant, PBK had
higher expression levels in PDTC compared with normal thyroid.
Therefore, PBK is also a potential therapeutic target, as it encodes a
mitotic protein, member of MAPK kinases family, which was
found to be over-expressed in haematological (Nandi et al, 2004)
and breast tumours (Park et al, 2006), and in PDTC cell lines
(Rodrigues et al, 2007). UHRF1 over-expression has been already
reported in lung (Jenkins et al, 2005) and breast (Hopfner et al,
2000) cancers. By conventional CGH analyses, the chromosomal
locus 19p13.3, where UHRF1 is located, was identified as a
common region of chromosomal gains in Hu ¨rthle cell thyroid
neoplasms (Wada et al, 2002) and recently, using array-CGH, gains
involving the 19p13 region were also found in 67% of ATC (Lee
et al, 2008). UHRF1 encodes a nuclear protein that transcription-
ally regulates TOP2A (Hopfner et al, 2000), an enzyme that
catalyses the breaking and rejoining of DNA strands, during
transcription. Interestingly, TOP2A showed a five-fold increase in
PDTC vs normal tissues (P¼0.02). In addition, UHRF1 is known
to regulate the retinoblastoma protein (Jeanblanc et al, 2005) and
is involved in the DNA damage response (Jenkins et al, 2005).
More recently, an essential role for UHRF1 in the control of DNA
methyltransferase 1 (DNMT1), the protein responsible for DNA
methylation maintenance in mammalian cells, has also been
reported (Bostick et al, 2007; Sharif et al, 2007). UHRF1 and
DNMT1 interactions have been shown to be involved in VEGF
regulation, a major pro-angiogenic protein (Achour et al, 2008).
Classification according to biological functions showed that
about 8.5% of the genes differentially expressed between PDTC
and normal tissues were downregulated and all related to cell
adhesion. Interestingly, by further analysis, we found that under-
expressed genes were mainly related to the cell membrane,
encoding receptors, transmembranar or extracellular proteins. In
agreement with this, the ITIH5 gene, which may have an essential
function in cell attachment and invasion, was under-expressed in
PDTC tumours. ITIH5 is a recently discovered member of the
inter-alpha (globulin) inhibitor heavy chains (ITIH) gene family
(Himmelfarb et al, 2004). In particular, the main function of ITIH
is based on their covalent linkage to hyaluronic acid, the major
component of the extracellular matrix. Therefore, deregulation of
ITIH proteins affects the stability of the extracellular matrix and
so, may promote tumour invasion and metastasis (Bost et al,
1998). Accordingly, ITIH genes have been shown to be down-
regulated in a variety of human tumours and have been proposed
as tumour suppressor or metastasis repressor genes (Hamm et al,
2008). ITIH5 downregulation in breast cancer, caused by promoter
hypermethylation, is associated with poorer clinical outcome, and
reduced protein expression was proved to be a bad prognostic
marker in invasive node-negative patients (Veeck et al, 2008). In
fact, we found that lower expression of ITIH5 was statistically
associated with larger tumours, as well as with more aggressive
cases, such as PDTC (reaching undetectable levels in the two PDTC
cell lines). Interestingly, we could also observe that extensively
invasive FTC had lower ITIH5 expression levels than minimally
invasive ones.
Compared with WDTC, PDTC had enriched gene sets (repre-
sented by over-expressed genes) associated earlier with cell cycle
and poor prognosis signatures. Interestingly, one of these sets
corresponded to a meta-signature of genes differentially over-
expressed in undifferentiated relatively to well-differentiated
cancers of different tissues (Rhodes et al, 2004). Among the most
represented genes in these sets were cell-cycle regulators (CDC2,
CCNB2, CDKN3 and TOP2A), as well as genes with a role in the
structure of the kinetochore and in the mitotic spindle assembly
checkpoint (MSAC) (CENPA, BUB1 and MAD2L1). We also found
statistically significant molecular signatures associated with the
BUB1 and BUB1 b (yeast) (BUB1B) genes. Some of these genes
were reported earlier to be over-expressed in advanced cases of
thyroid tumours (Montero-Conde et al, 2008; Wada et al, 2008).
These observations indicate that PDTC may have abnormalities in
MSAC or in the attachment of kinetochores, which may
compromise mitotic fidelity and contribute to chromosomal
instability. Accordingly, we observed earlier (Banito et al, 2007)
that four out of the five PDTC analysed in this study were
aneuploid.
In the analysis of genes differentially expressed between PDTC
and WDTC, we only identified two genes. One of these, the
3-phosphoinositide-dependent protein kinase-1 gene (PDPK1),
encodes a protein responsible for protein kinase B or AKT
activation. PI3K/AKT pathway has a central role in regulation of
apoptosis, proliferation and cell-cycle progression and its abnor-
mal activation is frequently found in cancers, including thyroid
tumours (Shinohara et al, 2007). Unexpectedly, and contrary to
other cancer types, we observed that PDPK1 gene was under-
expressed in PDTC.
The identification of molecular mechanisms involved in tumour
progression is important in the design of new strategies for
treating aggressive neoplasias, such as PDTC and ATC. For
instance, over-expression of UHRF1 in PDTC samples, a protein
that seems to be essential for DNMT1 function, indicates that
UHRF1 targeting may offer a new therapeutic approach for PDTC
cases. On the other hand, ITIH5 downregulation may be an
essential mechanism in thyroid tumourigenesis, especially in
tumour metastasis. In addition, and similarly to breast cancer,
ITIH5 may prove to be a useful prognostic marker.
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